Head-to-head · WeighScore
Eve vs Primary Clinic (Direct GLP)
The verdict
Eve takes it — 66.3/100 to 65.5/100, but only just.
Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual… Primary Clinic (Direct GLP) is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Eve | Primary Clinic (Direct GLP) |
|---|---|---|
| WeighScore | 66.3/100 | 65.5/100 |
| Grade | C | C |
| Scorecard rank | #189 | #219 |
| Semaglutide | $195/mo (compounded) | $85/mo (0.25-0.75 mg band, membership required, compounded) |
| Tirzepatide | $195/mo (compounded) | $133/mo (1.25-2.5 mg band, membership required, compounded) |
| Coverage | Coverage not published | 10 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #189 · C
Strengths
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Where it loses points
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Graded #219 · C
Strengths
- Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
- GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
- Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
- Routine labs and thousands of medications included in membership — no surprise bills
- Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide
Where it loses points
- The medication price is on top of an $89/mo direct-primary-care membership, which the FAQ states does not include the drug — all-in is about $174/mo for semaglutide and $222/mo for tirzepatide
- Prices are published as dose BANDS rather than per dose, and the cheapest tirzepatide band starts at 1.25 mg, below the 2.5 mg labelled starting dose
- The pricing is rendered entirely in JavaScript, so nothing on the page is readable without running the site's bundle
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.